Shares of EyePoint Pharmaceuticals dropped nearly 30% premarket on Monday after the company said its experimental eye disease treatment failed to meet a clinical trial’s main goal.
More Stories
A huge NASA contract has sent Intuitive Machines’ stock skyrocketing. This analyst sees even more upside.
Intuitive Machines is “the leading beneficiary of NASA’s lunar commercialization efforts,” says B. Riley Securities analyst Mike Crawford.
Oil on track for weekly gains after Fed rate cut, rising Middle East tensions
Oil futures were on track for solid weekly gains, boosted by the Federal Reserve’s large rate cut and a renewed...
FedEx’s earnings miss may be more of a speed bump than a brick wall, analyst says
Analysts sees a potential spinoff of FedEx’s freight business as a possible boost, but the stock is dropping sharply
If you’re not sure how to invest, it’s as easy as picking two funds.
Get peace of mind, plus a piece of the action
The Fed spurred a big rally in Nvidia and other chip stocks. Is it sustainable?
Fed commentary could give a further shot in the arm to AI names that have been market leaders, but the...
Analysts warned about the fallout from a surging yen. But then this happened.
Traders feared Japanese investors would bring money home as the yen carry-trade imploded. They were wrong.